Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec

Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet